← All trials
NCT04407208
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2020
- Primary completion
- Aug 1, 2020
- Completion date
- Aug 1, 2020
- First posted
- May 29, 2020
- Last posted
- May 29, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PT Bio FarmaLead sponsor
- PT Bio FarmaReponsible party - principal investigator
- PT Bio FarmaStudy director
- Eijkman Institute for Molecular Biology, Jakarta, IndonesiaCollaborator
- Rumah Sakit Pusat Angkatan Darat Gatot SoebrotoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.